中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
18期
436-438,439
,共4页
CD137mAb%CIK细胞%宫颈癌
CD137mAb%CIK細胞%宮頸癌
CD137mAb%CIK세포%궁경암
CD137mAb%CIK cells%Cervical cancer patients
目的探讨 CD137mAb 对宫颈癌患者 CIK 细胞的功能调节。方法分离宫颈癌患者外周血单个核细胞（PBMCs）,常规 CIK 培养体系中加入 CD137mAb 为实验组（CD137-CIK 组），同时对照组加入鼠 IgG1同型对照（IgG1-CIK 组）。动态观察 CIK 细胞体外增殖；流式检测 CIK细胞凋亡率、细胞表型及 CD3+CD56+细胞内因子的表达；LDH 酶释放法检测 CIK 细胞杀伤活性。结果两组 CIK 细胞均有很强的增殖活性，实验组细胞浓度最高达（20.92±3.57）×106/mL，对照组为（14.02±2.68）×106/mL（P ＜0.05）；第21天实验组和对照组 CD3+CD56+细胞比例分别达到（35.48±5.46）％和（25.12±4.18）％（P ＜0.05）；CD137-CIK 组细胞凋亡坏死率明显低于 IgG1-CIK 组；实验组 CIK 细胞体外杀伤宫颈癌 HeLa 细胞株活性明显高于对照组（P ＜0.05）；流式检测 CD137-CIK 组中 CD3+CD56+细胞内 IL-2，IFN-γ表达上调，IL-4，IL-10表达下调。结论 CD137mAb 介导的共刺激信号可以显著提高宫颈癌患者 CIK 细胞的体外增殖活性和抗瘤作用。
目的探討 CD137mAb 對宮頸癌患者 CIK 細胞的功能調節。方法分離宮頸癌患者外週血單箇覈細胞（PBMCs）,常規 CIK 培養體繫中加入 CD137mAb 為實驗組（CD137-CIK 組），同時對照組加入鼠 IgG1同型對照（IgG1-CIK 組）。動態觀察 CIK 細胞體外增殖；流式檢測 CIK細胞凋亡率、細胞錶型及 CD3+CD56+細胞內因子的錶達；LDH 酶釋放法檢測 CIK 細胞殺傷活性。結果兩組 CIK 細胞均有很彊的增殖活性，實驗組細胞濃度最高達（20.92±3.57）×106/mL，對照組為（14.02±2.68）×106/mL（P ＜0.05）；第21天實驗組和對照組 CD3+CD56+細胞比例分彆達到（35.48±5.46）％和（25.12±4.18）％（P ＜0.05）；CD137-CIK 組細胞凋亡壞死率明顯低于 IgG1-CIK 組；實驗組 CIK 細胞體外殺傷宮頸癌 HeLa 細胞株活性明顯高于對照組（P ＜0.05）；流式檢測 CD137-CIK 組中 CD3+CD56+細胞內 IL-2，IFN-γ錶達上調，IL-4，IL-10錶達下調。結論 CD137mAb 介導的共刺激信號可以顯著提高宮頸癌患者 CIK 細胞的體外增殖活性和抗瘤作用。
목적탐토 CD137mAb 대궁경암환자 CIK 세포적공능조절。방법분리궁경암환자외주혈단개핵세포（PBMCs）,상규 CIK 배양체계중가입 CD137mAb 위실험조（CD137-CIK 조），동시대조조가입서 IgG1동형대조（IgG1-CIK 조）。동태관찰 CIK 세포체외증식；류식검측 CIK세포조망솔、세포표형급 CD3+CD56+세포내인자적표체；LDH 매석방법검측 CIK 세포살상활성。결과량조 CIK 세포균유흔강적증식활성，실험조세포농도최고체（20.92±3.57）×106/mL，대조조위（14.02±2.68）×106/mL（P ＜0.05）；제21천실험조화대조조 CD3+CD56+세포비례분별체도（35.48±5.46）％화（25.12±4.18）％（P ＜0.05）；CD137-CIK 조세포조망배사솔명현저우 IgG1-CIK 조；실험조 CIK 세포체외살상궁경암 HeLa 세포주활성명현고우대조조（P ＜0.05）；류식검측 CD137-CIK 조중 CD3+CD56+세포내 IL-2，IFN-γ표체상조，IL-4，IL-10표체하조。결론 CD137mAb 개도적공자격신호가이현저제고궁경암환자 CIK 세포적체외증식활성화항류작용。
Objective To investigate the effect of CD137mAb on regulation of CIK cells’ function of cervical cancer patients.Methods CIK cells were generated by CD3mAb, IL-2, IFN-γ induced from peripheral blood mononuclear cells of cervical cancer patients.Experimental group was added CD137mAb and control group was added mouse IgG1 isotype control, separately.The related phenotypes and the apoptosis of CIK cells and the cytokines production of CD3+CD56+cells were detected by flow cytometry.Cell proliferation was evaluated by cell counting with trypan blue exclusion test.The anti-tumor activity of the CIK cells was determined by LDH Cytotoxicity assay.Results The concentration was respectively arrived at(20.92±3.57)×106/mL and (14.02±2.68) ×106/mL (P<0.05); The flow cytometry analysis showed that the percentage of CD3+CD56+ cells increased from (0.48±0.25)% on day 0 to (35.48±5.46)%and (25.12±4.18)%(p<0.05)on day 21; The rate of apoptosis and necrosis of IgG1-CIK cells was higher than CD137-CIK cells; The cells possessed stronger anti-tumor cytotoxic activity in vitro than IgG1-CIK cells; In addition, the production of IFN-γ and IL-2 was increased and the IL-4 and IL-10 was decreased significantly in CD3+CD56+cells of CD137-CIK cells.Conclusion CD137 signaling could significantly regulate the function of CIK cells from cervical cancer patients, which may provide a new way to treat the cervical cancer.
